Centre for Clinical Transfusion Medicine, 72076 Tübingen, Germany.
NMI Natural and Medical Sciences Institute, University Tübingen, 72770 Reutlingen, Germany.
Viruses. 2022 Dec 25;15(1):65. doi: 10.3390/v15010065.
As the Corona Disease 2019 (COVID-19) caused by SARS-CoV-2 persists, vaccination is one of the key measures to contain the spread. Side effects (SE) from vaccination are one of the reasons for reluctance to vaccinate. We systematically investigated self-reported SE after the first, second, and booster vaccinations. The data were collected during the TüSeRe: exact study (Tübinger Monitoring Studie zur exakten Analyse der Immunantwort nach Vakzinierung). Employees of health and research institutions were invited to participate. Study participants were asked to fill out an online questionnaire and report their SE after each dose of SARS-CoV-2 vaccination. A total of 1046 participants (mean age: 44 ± 12.9 years; female, = 815 (78%); male, = 231 (22%)) were included in the analysis. Local and systemic SE were more frequent after receiving the vector-based vaccine ChAdOx1 nCoV-19 in the first vaccination. However, local and systemic SE were more common after receiving mRNA vaccines (BNT162b2, mRNA-1273) in the second vaccination. Compared to the BNT162b2 vaccine, more SE have been observed after receiving the mRNA-1273 vaccine in the booster vaccination. In multivariate analysis, local and systemic side effects were associated with vaccine type, age and gender. Local and systemic SE are common after SARS-CoV-2 vaccines. The frequency of self-reported local and systemic SE differ significantly between mRNA and vector-based vaccines.
由于严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）持续存在，疫苗接种是遏制其传播的关键措施之一。疫苗接种的副作用（SE）是人们不愿接种疫苗的原因之一。我们系统地调查了首次、第二次和加强接种后自我报告的 SE。这些数据是在 TüSeRe：精确研究（Tübinger Monitoring Studie zur exakten Analyse der Immunantwort nach Vakzinierung）中收集的。邀请卫生和研究机构的员工参加。研究参与者被要求填写在线问卷，并报告每次接种 SARS-CoV-2 疫苗后的 SE。共有 1046 名参与者（平均年龄：44 ± 12.9 岁；女性， = 815（78%）；男性， = 231（22%））被纳入分析。在首次接种时，基于载体的 ChAdOx1 nCoV-19 疫苗接种后更常出现局部和全身 SE。然而，在第二次接种时，mRNA 疫苗（BNT162b2、mRNA-1273）接种后更常出现局部和全身 SE。与 BNT162b2 疫苗相比，在加强接种时，接种 mRNA-1273 疫苗后观察到更多的 SE。在多变量分析中，局部和全身副作用与疫苗类型、年龄和性别有关。SARS-CoV-2 疫苗接种后常出现局部和全身 SE。mRNA 和基于载体的疫苗之间自我报告的局部和全身 SE 的频率存在显著差异。
